Literature DB >> 24220704

Reference range for the antimüllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram.

Scott M Nelson1, Stamatina Iliodromiti2, Richard Fleming2, Richard Anderson3, Alex McConnachie4, Claudia-Martina Messow4.   

Abstract

OBJECTIVE: To develop an optimal model and age-specific centiles for the decline in antimüllerian hormone (AMH) as measured by the new Beckman Coulter AMH Generation II (Gen II) assay and compare this to the previous nomogram derived for the Diagnostics Systems Laboratory (DSL) assay.
DESIGN: Multicenter retrospective population study, with validation of linear, biphasic linear, differential, power, and quadratic equations.
SETTING: Two clinical pathology laboratories. PATIENT(S): A new cohort of 10,984 women aged 25 to 45 years old attending infertility clinics, randomly divided into a training cohort of 5,492 women and a validation cohort of 5,492 women, and an existing cohort of 9,601 women, who had contributed to the development and validation of a nomogram for AMH measured by the DSL assay. INTERVENTION(S): Serum measurement of AMH as determined by the Beckman Coulter AMH Generation II assay in 10,984 women. MAIN OUTCOME MEASURE(S): Optimal model for the decline in AMH as measured by the AMH Gen II assay with age, with age-specific 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles. RESULT(S): A quadratic model defined as (2.431 + 0.089 * Age + -0.003 * Age(2)) fitted the decline in AMH with age. The anticipated 40% increase in age-specific population values relative to the previously validated DSL assay nomogram was not observed. CONCLUSION(S): Age-specific reference ranges for the AMH gen II assay suggest a systematic shift in assay calibration since initial evaluation and commercial release of the AMH Gen II assay.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical pregnancy; GnRH agonist; GnRH antagonist; luteal support; ovarian hyperstimulation syndrome

Mesh:

Substances:

Year:  2013        PMID: 24220704     DOI: 10.1016/j.fertnstert.2013.10.021

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  19 in total

1.  Serum antimüllerian hormone measurements with second generation assay at two distinct menstrual cycle phases for prediction of cycle cancellation, pregnancy and live birth after in vitro fertilization.

Authors:  Carolina P Rezende; Ana L Rocha; Cynthia Dela Cruz; Lavinia E Borges; Helen L Del Puerto; Fernando M Reis
Journal:  J Assist Reprod Genet       Date:  2014-07-12       Impact factor: 3.412

Review 2.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

3.  Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Authors:  Crystal Chan; Kimberly Liu
Journal:  J Assist Reprod Genet       Date:  2014-08-12       Impact factor: 3.412

4.  Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.

Authors:  K A Kissell; M R Danaher; E F Schisterman; J Wactawski-Wende; K A Ahrens; K Schliep; N J Perkins; L Sjaarda; J Weck; S L Mumford
Journal:  Hum Reprod       Date:  2014-06-12       Impact factor: 6.918

Review 5.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

6.  Recalled maternal lifestyle behaviors associated with anti-müllerian hormone of adult female offspring.

Authors:  Allison A Eubanks; Carrie J Nobles; Micah J Hill; Alan H DeCherney; Keewan Kim; Lindsey A Sjaarda; Neil J Perkins; Aijun Ye; Jessica R Zolton; Robert M Silver; Enrique F Schisterman; Sunni L Mumford
Journal:  Reprod Toxicol       Date:  2020-09-09       Impact factor: 3.143

7.  Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome.

Authors:  Sunni L Mumford; Richard S Legro; Michael P Diamond; Christos Coutifaris; Anne Z Steiner; William D Schlaff; Ruben Alvero; Gregory M Christman; Peter R Casson; Hao Huang; Nanette Santoro; Esther Eisenberg; Heping Zhang; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2016-05-26       Impact factor: 5.958

Review 8.  Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR.

Authors:  Lisa M Pastore; Mindy S Christianson; James Stelling; William G Kearns; James H Segars
Journal:  J Assist Reprod Genet       Date:  2017-10-02       Impact factor: 3.412

9.  Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.

Authors:  Agnese Barnabei; Lidia Strigari; Paolo Marchetti; Valentina Sini; Liana De Vecchis; Salvatore Maria Corsello; Francesco Torino
Journal:  Oncologist       Date:  2015-09-04

10.  Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity.

Authors:  Flavia Magri; Lucia Schena; Valentina Capelli; Margherita Gaiti; Francesca Zerbini; Emanuela Brambilla; Mario Rotondi; Mara De Amici; Arsenio Spinillo; Rossella E Nappi; Luca Chiovato
Journal:  Reprod Biol Endocrinol       Date:  2015-09-21       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.